RE:RE:VicarioJust a reminder what "solid" means to management in this growth-stage company.
From the 2016 MD&A:
"We expect our base business in cosmeceuticals to remain very solid over the next 12 months".
Actual result was decrease in sales of 5.5%.
From the 2017 MD&A:
"Ceapro has all the key ingredients in place for success and is poised for another solid year in 2018".
Actual result was decrease in sales of 10.3% (despite their record Q4).
So yes, I'm sure they will have another "solid" year. And this is why they desparately need to actually get even a single PGX deal.